GLOBE Model: Executive Summary and Strategic Architecture Analysis

ValuesEdge Institutional Intelligence | Based on CMS Model Page (Last Modified: October 2, 2026)

---

1. Executive Summary and Strategic Context

What Is GLOBE and What Problem Does It Solve?

The Global Benchmark for Efficient Drug Pricing (GLOBE) Model is a mandatory CMS Innovation Center (CMMI) payment model operating under Section 1115A of the Social Security Act. It targets a foundational structural dysfunction in Medicare Part B drug pricing: Americans pay more than four times as much for brand-name prescription drugs as people in other developed countries, and Medicare Part B drug spending has grown more rapidly than overall national drug spending — compounding costs for beneficiaries and the broader program alike.

GLOBE's core mechanism is a manufacturer rebate system triggered when the price of a Part B drug to Original Medicare exceeds an international benchmark derived from prices paid in economically comparable countries. The rebate functions as a financial correction: it pulls the net cost to Medicare for qualifying drugs toward international market rates. Simultaneously, beneficiary coinsurance obligations are tied to the international benchmark price rather than the current inflated U.S. price — directly reducing out-of-pocket exposure for Medicare Part B enrollees who receive GLOBE Model drugs.

The model is categorized under Prescription Drug Models and sits within CMMI's portfolio as a test of an alternative calculation methodology for pharmaceutical manufacturer rebates under the existing Medicare Part B Drug Inflation Rebate Program. Rather than replacing that program wholesale, GLOBE tests a different formula: one anchored to international net pricing data rather than domestic inflation thresholds. Rebates collected under GLOBE are remitted directly to the Medicare Supplementary Medical Insurance (SMI) Trust Fund, preserving the existing fiscal architecture while changing the pricing logic.

Therapeutic Scope: Which Drugs Are Targeted?

GLOBE does not apply to all Part B drugs. It targets single-source drugs and sole-source biological products — the categories most insulated from generic or biosimilar competition and therefore most likely to sustain high price premiums. Eligible drugs must fall within the following five therapeutic classes: oncology, rheumatology, immunology, ophthalmology, and endocrinology (with certain exceptions). Within those classes, a drug qualifies only if annual Original Medicare spending exceeds $100 million — a threshold that concentrates the model on high-expenditure agents where pricing inefficiency has the greatest fiscal impact.

The shared clinical profile of targeted drugs — cancer therapies, autoimmune treatments, arthritis drugs, conditions managed in ophthalmology and endocrinology — reflects a deliberate design logic. These are drugs administered in clinical settings (physician offices, infusion centers, hospital outpatient departments), billed under Part B's buy-and-bill reimbursement framework, and used by beneficiaries managing serious chronic or life-threatening conditions. CMS explicitly identifies these as areas where "potentially avoidable high program expenditures and access barriers due to high costs likely contribute to deficits in care" — framing drug unaffordability not merely as a fiscal problem but as a quality-of-care deficit.

Strategic Significance for the Value-Based Care Market

GLOBE does not directly restructure provider payment — it targets pharmaceutical manufacturers as the mandatory participants. However, its downstream implications for the value-based care market are substantial.

For oncology practices, rheumatology groups, and infusion centers, GLOBE will change the net revenue environment for some of the highest-volume, highest-margin Part B drugs. Under buy-and-bill, providers acquire drugs at acquisition cost and are reimbursed at Average Sales Price (ASP) plus a percentage add-on. GLOBE's rebate mechanism adjusts the net cost to Medicare, and critically, the Original Medicare Part B payment to providers and suppliers is adjusted when the beneficiary coinsurance reduction applies — the Medicare payment becomes "the allowed amount minus the GLOBE Model beneficiary coinsurance amount, subject to other applicable adjustments." This linkage means provider reimbursement calculations will be affected by GLOBE's pricing realignment, not only manufacturer revenues.

For ACOs and integrated delivery systems, lower beneficiary coinsurance for GLOBE drugs could reduce cost-sharing barriers that currently drive non-adherence or delayed initiation of therapy — a dynamic that often generates downstream costs (hospitalizations, disease progression) that show up in total cost of care calculations. Improved drug adherence for beneficiaries in oncology and immunology could favorably affect quality measures and total cost of care benchmarks in ACO and value-based arrangements.

For Medicare Advantage plans, GLOBE applies only to Original Medicare Part B — it does not directly regulate MA drug pricing. However, if GLOBE suppresses Part B drug costs meaningfully in the fee-for-service sector, it could influence competitive bidding dynamics and benchmark calculations affecting MA plan financials over time.

Political Context and Administrative Alignment

GLOBE was finalized under the current Trump administration (CMS Administrator Dr. Mehmet Oz, CMMI Director Abe Sutton), representing a significant policy choice: a mandatory, internationally benchmarked drug pricing intervention advanced under a Republican administration. The model draws explicit authority from the Most Favored Nation conceptual framework that animated Trump's first-term executive orders on drug pricing — using international reference pricing as a lever to discipline domestic pharmaceutical prices. The international comparator list (19 countries, including France, Germany, Japan, the UK, Canada, and others) reflects the same set of economically comparable nations frequently cited in prior Republican and Democratic drug pricing proposals alike.

The mandatory nature of the model — participation is required for manufacturers of qualifying drugs, with no opt-out — signals that CMS under the current administration is willing to use CMMI's 1115A authority aggressively in the drug pricing domain, even when that authority creates friction with the pharmaceutical industry. The alignment with HHS Secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" policy posture — which includes skepticism of high pharmaceutical costs — provides additional political cover for a model that constrains manufacturer pricing latitude.

Market Transformation Implications

GLOBE represents the most structurally direct test of international reference pricing in the history of the Medicare program. If the model demonstrates that benchmark-linked rebates reduce program expenditure without diminishing beneficiary access to or quality of care across oncology, rheumatology, immunology, ophthalmology, and endocrinology, it will generate the evidentiary foundation for legislative or regulatory expansion beyond the model's test parameters.

The mandatory participation structure means manufacturers cannot avoid the model for qualifying drugs — removing the adverse selection dynamic that has undermined prior voluntary CMMI models. This design choice is itself a signal: CMMI is treating GLOBE as a genuine population-level test, not an opt-in pilot. The breadth of the 19-country reference panel and the provision allowing manufacturers to submit their own international net pricing data introduces a negotiation dynamic that could drive manufacturers to voluntarily surface lower net prices in order to influence their benchmark — a form of soft price disclosure with structural consequences.

For hospital executives and physician group administrators managing large Part B drug portfolios, GLOBE's January 1, 2027 launch demands proactive financial modeling of which specific drugs in their formularies and infusion protocols are likely to fall within the model's scope, and what adjusted reimbursement levels may look like once the international benchmark is applied.

---

2. Model Architecture and Payment Structure

Participation Structure

GLOBE's participant category is pharmaceutical manufacturers, not providers, health systems, or ACOs. Participation is mandatory for any manufacturer of a Medicare Part B drug that meets the GLOBE Model drug eligibility criteria and is not otherwise excluded. This mandatory structure is operationally significant: it removes manufacturer optionality and ensures the model generates a complete, non-self-selected population of qualifying drugs for evaluation.

Manufacturers have one area of voluntary election: they may choose to submit international drug net pricing data through the process established in the GLOBE Model final rule. This voluntary data submission mechanism is strategically important. If a manufacturer's actual international net prices (after rebates, discounts, and other concessions in foreign markets) are lower than the benchmark CMS would otherwise derive from commercially available data sources, submitting proprietary data could result in a lower rebate obligation. Conversely, if commercially available data underestimates the international net price, voluntary submission could work against the manufacturer. This creates a sophisticated incentive calculus that will require manufacturers to conduct detailed internal pricing audits across the 19 reference countries.

Drug eligibility requires all of the following:

• Classified as a single-source drug or sole-source biological product
• Falls within oncology, rheumatology, immunology, ophthalmology, or endocrinology therapeutic classes (subject to certain exceptions)
• Annual Original Medicare spending exceeds $100 million

Providers and suppliers administering GLOBE Model drugs are affected by the model's payment adjustments and beneficiary coinsurance reductions, but they are not classified as "participants" — their engagement with GLOBE is automatic based on geographic inclusion criteria applied to their patient population.

Benchmark Construction: The 19-Country Reference Panel

The international benchmark — the central pricing reference against which U.S. Part B drug costs are measured — is derived from one of two sources:

1. Manufacturer-reported international drug net pricing data (voluntarily submitted)
2. Commercially available international drug pricing information from data sources for economically similar reference countries

The 19 reference countries are: Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, the Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, and the United Kingdom.

This panel is notable for its breadth and diversity — it includes both high-income Western European nations with well-established reference pricing systems (France, Germany, Netherlands) and countries with different regulatory structures (Israel, South Korea, Czech Republic). The inclusion of countries with varying GDP levels and healthcare systems within the "economically comparable" designation reflects an intent to construct a robust composite benchmark rather than cherry-pick the lowest or highest international prices.

Payment Methodology and Rebate Mechanics

The rebate mechanism functions as follows:

• When the price of a GLOBE Model drug to Original Medicare exceeds the international benchmark, the manufacturer owes a rebate representing the excess
• Rebates are paid directly to the Medicare Supplementary Medical Insurance Trust Fund — not to providers, plans, or intermediaries
• The model tests an alternative calculation for rebates under the existing Medicare Part B Drug Inflation Rebate Program, using the international benchmark in place of the standard inflation-based threshold

Beneficiary coinsurance is directly linked to the international benchmark: beneficiaries receiving GLOBE Model drugs pay coinsurance calculated on the benchmark price, not the full U.S. ASP-based price. This produces a concurrent dual effect: Medicare's net drug cost is reduced via manufacturer rebates, and beneficiary out-of-pocket exposure is reduced via benchmark-linked coinsurance.

Provider/supplier payment adjustment: The Original Medicare Part B payment to providers and suppliers is modified when the GLOBE Model beneficiary coinsurance reduction applies. Specifically, the Medicare payment equals the allowed amount minus the GLOBE Model beneficiary coinsurance amount, subject to other applicable adjustments. This adjustment structure means the provider receives the Medicare portion calculated against the benchmark-adjusted allowed amount — a mechanism that providers and their billing teams will need to operationalize and track separately from standard Part B reimbursement.

Model Timeline

Milestone	Date
Model launch	January 1, 2027
Beneficiary coinsurance reduction begins	April 1, 2027
Model performance period ends	March 31, 2032
Beneficiary coinsurance reduction ends	March 31, 2032
Rebate invoicing and reconciliation concludes	2034

The 5-year and 3-month performance period (January 1, 2027 – March 31, 2032) provides a sufficiently long evaluation window to assess access, quality, and expenditure outcomes across the targeted therapeutic classes. The tail period extending to 2034 for rebate invoicing and reconciliation reflects the administrative complexity of settling manufacturer rebate obligations — a timeline that pharmaceutical manufacturers should build into their financial forecasting and reserve structures now.

The 3-month gap between model launch (January 1, 2027) and coinsurance reduction activation (April 1, 2027) is operationally significant: the first quarter of the model will involve active manufacturer participation and rebate calculation without the beneficiary coinsurance reduction yet in effect. This staging likely reflects the administrative lead time required to recalibrate coinsurance amounts in Medicare systems and communicate changes to beneficiaries, supplemental insurers (Medigap plans), and providers.

Performance Measures and Quality Requirements

The source documents do not specify discrete quality metrics, performance measures, or reporting thresholds for GLOBE. CMS's stated intent is that the model will preserve or enhance beneficiaries' quality of care — language that signals quality monitoring will occur but does not specify the measurement framework. Given CMMI's standard evaluation methodology for mandatory models, it is reasonable to expect that CMS will track access to GLOBE Model drugs (utilization rates relative to pre-model baselines), beneficiary out-of-pocket costs, and Medicare program expenditure as primary evaluation endpoints. However, institutional stakeholders should not presume the existence of provider-facing quality reporting requirements based on available source materials.

Key Structural Design Choices: What They Signal

Design Feature	Policy Signal
Mandatory manufacturer participation	Eliminates adverse selection; treats GLOBE as a genuine population-level test
19-country reference panel	Constructs a robust composite benchmark; resists cherry-picking
Voluntary manufacturer pricing data submission	Creates soft price disclosure incentive; gives manufacturers partial pricing agency
Rebates to SMI Trust Fund (not providers)	Maintains program solvency focus; does not redistribute to providers
Coinsurance tied to benchmark	Directly improves beneficiary affordability; not offset by Medigap or secondary coverage dynamics in the same way full-price coinsurance is
Reconciliation tail to 2034	Reflects rebate accounting complexity; manufacturers must reserve appropriately
$100M annual spending threshold	Concentrates model on highest-expenditure agents; maximizes fiscal impact per drug included

---

This analysis is based exclusively on the CMS GLOBE Model page (last modified October 2, 2026). Institutional stakeholders should consult the GLOBE Model Final Rule published in the Federal Register for complete regulatory text, drug-specific eligibility determinations, and manufacturer compliance requirements.